-->

Tag: Libtayo

Home / Established Year

, , , ,

Cemiplimab-rwlc is approved by FDA in combination with platinum-based chemotherapy for non-small cell lung cancer

November 2022: The combination of cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) and platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 abnormalit..

, , , , ,

Cemiplimab-rwlc has been approved by the FDA for the treatment of locally progressed and metastatic basal cell carcinoma

August 20, 2021: The FDA has given cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) regular approval for patients with locally advanced basal cell carcinoma (laBCC) who have previously been treated with a hedgehog pathwa..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy